Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 3

Conditions

Wilms Tumor 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4Neuroblastoma 4Medulloblastoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4Glioma 4Ependymoma 4Sarcoma 3Rhabdomyosarcoma 3Osteosarcoma 3Multiple Myeloma 3Central Nervous System Neoplasms 3Sarcoma, Ewing 2Xanthogranuloma, Juvenile 1Histiocytic Sarcoma 1Familial ependymoma 1

Interventions

Dexamethasone 277Lenalidomide 155Bortezomib 152Cyclophosphamide 115Melphalan 107Calcium Dobesilate 107fludarabine phosphate 70carfilzomib 61pomalidomide 55Peripheral Blood Stem Cell Transplantation 53Whole-Body Irradiation 52Mycophenolic Acid 52Granulocyte Colony-Stimulating Factor 52Filgrastim 52daratumumab 46fludarabine 43Tacrolimus 41ixazomib 40Busulfan 40Thalidomide 36Cyclosporine 32dexamethasone acetate 26Stem Cell Transplantation 26Antilymphocyte Serum 25dexamethasone 21-phosphate 22plerixafor 20auricularum 20belantamab mafodotin 19Prednisone 19Etoposide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Multiple Myeloma × Nuclear Medicine Department, Hospital × Clear all
NCT06357988 2026-05-28

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06385483 2026-05-28

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
19 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06390826 2026-05-28

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
10 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡